Eli Lilly's Phase 3 study of tirzepatide showed sustained weight loss and nearly 99% remaining diabetes-free at 176 weeks.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing

Eli Lilly's Phase 3 study of tirzepatide showed sustained weight loss and nearly 99% remaining diabetes-free at 176 weeks.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing